Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling

Karthick Harini,Suliman Yousef Alomar,Mohammed Vajagathali,Salim Manoharadas,Anbazhagan Thirumalai,Koyeli Girigoswami,Agnishwar Girigoswami
DOI: https://doi.org/10.3390/ph17030366
IF: 4.6
2024-03-12
Pharmaceuticals
Abstract:Bupropion (Bup) belongs to the norepinephrine–dopamine reuptake inhibitor (NDRI) class and it is the only FDA-approved drug of its class for the treatment of major depressive disorder (MDD), sold under the name of Wellbutrin. Although bupropion is effective in suppressing the symptoms, its regular use and overdose might lead to seizures and liver failure. Thus, we aimed to nanoformulate bupropion onto a niosomal vesicle to improve its efficacy and achieve the same therapeutic effect at lower scheduled doses. A thin film hydration method was adopted to synthesize and optimize Bup entrapped niosomes using three different surfactants of the sorbitan ester series (Span 20, 40, and 60) in combination with cholesterol. The optimization data determined that the niosome formulated with a cholesterol-to-surfactant ratio of 1:1.5 is the most stable system, with the Bup entrapped niosomes containing Span 20 (Bup@N20C) exhibiting minimal in vitro and in vivo toxicity, and demonstrating the sustained release of Bup in artificial cerebrospinal fluid (ACSF). The Bup@N20C formulation showed increased exploration activity and reduced irregular movements in reserpine-induced depression in the adult zebrafish model, suggesting the potential for mood improvement through the suppression of depression-like behavior which was established by statistical analysis and trajectory data. The Bup@N20C-treated group even surpasses the treatment effect of the positive control group and is comparable to the control group. Hence, it can be inferred that niosomal formulations of Bup represent a promising delivery system capable of achieving the brain delivery of the cargo by bypassing the blood–brain barrier facilitated by their small architectural structure.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to improve the delivery system of Bupropion through nanotechnology, in order to enhance its therapeutic effect and reduce side effects. Specifically: 1. **Enhancing the efficacy of Bupropion**: Bupropion is an effective antidepressant, belonging to the norepinephrine - dopamine reuptake inhibitor (NDRI). However, its regular use and overuse may lead to serious side effects such as seizures and liver failure. Therefore, researchers hope to achieve the same therapeutic effect at a lower dose by encapsulating Bupropion into niosomes. 2. **Reducing side effects**: By optimizing the formula of niosomes, researchers hope to reduce the toxicity and side effects of Bupropion, especially for problems that may occur during high - dose use. 3. **Improving brain delivery**: Bupropion needs to cross the blood - brain barrier (BBB) to exert its effect, and this process is a challenge for many drugs. Due to their small structure and good biocompatibility, niosomes can cross the blood - brain barrier more effectively, thereby improving the drug delivery efficiency in the brain. 4. **Exploring new treatment frontiers**: Through behavioral analysis, researchers evaluated the therapeutic potential of Bupropion encapsulated in niosomes, especially in the application of depression models. The experimental results show that this new - type delivery system can significantly improve depression symptoms and is more effective than traditional drug - administration methods. In conclusion, this paper aims to improve the delivery system of Bupropion through nanotechnology to achieve higher therapeutic effects, lower side effects, and better brain - delivery capabilities, thereby providing a safer and more effective treatment option for patients with depression. ### Key methods and results - **Synthesis and optimization**: Niosomes containing Bupropion were synthesized by the thin - film hydration method and optimized with different proportions of cholesterol and surfactants (Span 20, 40, 60). - **Stability assessment**: The optimal ratio of cholesterol to surfactant was determined to be 1:1.5. Among them, the Bupropion niosome containing Span 20 (Bup@N 20C) showed the lowest in - vitro and in - vivo toxicity and exhibited sustained - release characteristics. - **Behavioral analysis**: In the adult zebrafish model, Bup@N 20C showed increased exploratory activity and reduced abnormal movement, indicating its potential mood - improving effect. - **Statistical analysis**: The effectiveness of Bup@N 20C in suppressing depression - like behaviors was verified through statistical analysis and trajectory data, and it even exceeded the effect of the positive control group. These results indicate that niosomes, as a new - type delivery system, are expected to become an ideal carrier for Bupropion and other similar drugs.